Anti-CD37 targeted immunotherapy of B-Cell malignancies
CD37 is a member of tetra-spanning superfamily (characterized by their four transmembrane domains). It is one of the specific proteins for normal and malignant mature B cells. Anti CD37 monoclonal antibodies are reported to improve the overall survival in CLL. These therapeutics will increase the efficacy and reduce the toxicity in patients with both newly diagnosed and relapsed and refractory disease. Recent clinical trials have shown promising outcomes for these agents, administered both as monotherapy and in combination with standard chemotherapeutics. Long-term follow-up of combination regimens has even raised the question of whether the patients with CLL could be treated with intensive chemo-immunotherapy. In the present study, CD37 is introduced as an appealing target to treat B cell malignancies. The anti-CD37 antibodies as one of the most successful therapeutics against CD37 are introduced and the clinical outcomes of their exploitation are explained.
KeywordsCD37 Chronic lymphocytic leukemia Monoclonal antibody Non-Hodgkin lymphoma Otlertuzumab TRU-016
The authors thank Shahid Rajaee Teacher Training University and Zanjan University of Medical Sciences for support to conduct this work.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- Deckert J et al (2015) IMGN529, a novel antibody-drug conjugate (ADC) targeting CD37 shows synergistic activity with rituximab in non-Hodgkin lymphoma (NHL) models. Blood 126:1548Google Scholar
- Hellman A et al (2013) Phase 2 study of otlertuzumab (TRU-016), an anti-CD37 ADAPTIRTM protein, in combination with bendamustine vs bendamustine alone in patients with relapsed chronic lymphocytic leukemia (CLL). Blood 122:2860Google Scholar
- Kolstad A (2016) Efficacy and safety results of Betalutin®(177 Lu-DOTA-HH1) in a phase 1/2 study of patients with non-hodgkin B-cell lymphoma (NHL). Platelets 10:100Google Scholar
- Reichert JM (2012) Marketed therapeutic antibodies compendium, vol 3. Taylor & Francis, Abingdon, pp 413–415Google Scholar
- Reichert JM (2014) Antibodies to watch in 2014: mid-year update, vol 4. Taylor & Francis, Abingdon, pp 799–802Google Scholar
- Stathis A et al (2014a) A phase I study of IMGN529, an antibody-drug conjugate (ADC) targeting CD37, in adult patients with relapsed or refractory b-cell non-hodgkin’s lymphoma (NHL). Blood 124:1760Google Scholar
- Stathis A et al (2014b) Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL). J Clin Oncol 35(15):8526Google Scholar